Novartis gives up on anti-CD40 antibody to treat Sjögren's due to 'benefit/risk profile'

Novartis gives up on anti-CD40 antibody to treat Sjögren's due to 'benefit/risk profile'

Submitted by admin on January 31, 2025 - 11:14am
Source: 
Fierce Biotech
News Tags: 
Novartis
iscalimab
Sjögren’s syndrome
Headline: 
Novartis gives up on anti-CD40 antibody to treat Sjögren's due to 'benefit/risk profile'
snippet: 

Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome.

Do Not Allow Advertisers to Use My Personal information